✦ LIBER ✦

1411 CF102 FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION STUDY

✍ Scribed by Stemmer, S.M.; Benjaminov, O.; Medalia, G.; Ciuraru, N.B.; Silverman, M.H.; Bar-Yehuda, S.; Fishman, S.; Harpaz, Z.; Farbstein, M.; Cohen, S.; Patoka, R.; Singer, B.; Kerns, W.D.; Fishman, P.

Book ID: 122941793
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 62 KB
Volume: 56
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(12)61422-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I dose escalation trial of yttri

A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma

✍ Frances A. Shepherd; Lorne E. Rotstein; Sylvain Houle; Tsui-Chun K. Yip; Karen P 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 489 KB 👁 2 views

A Phase I, open-label, dose-escalation s

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors

✍ Michael S. Gordon,David S. Mendelson,Mitchell Gross… 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 200 KB

Results following treatment to doses of

Results following treatment to doses of 92.4 or 102.9 Gy on a phase I dose escalation study for non-small cell lung cancer

✍ Narayan, Samir; Henning, George T; Ten Haken, Randall K; Sullivan, Molly A; Mart 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 113 KB

Safety and Efficacy of PF-3512676 for th

Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study

✍ John A. Thompson; Timothy Kuzel; Beverly J. Drucker; Walter J. Urba; Ronald M. B 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 140 KB

Dysport® for the treatment of myofascial

Dysport® for the treatment of myofascial back pain: Results from an open-label, Phase II, randomized, multicenter, dose-ranging study

✍ Gerhard H.H. Müller-Schwefe; Michael A. Überall 📂 Article 📅 2011 🏛 Walter de Gruyter GmbH 🌐 English ⚖ 249 KB

A 1-Year, Open Label, Randomized Phase I

A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North America

✍ Gittelman, Marc; Pommerville, Peter J.; Persson, Bo-Eric; Jensen, Jens-Kristian; 📂 Article 📅 2008 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 290 KB